26 completed, 7 terminated, 2 withdrawn. 35 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 35 | Completed 26, Terminated 7, Withdrawn 2 |
| Phase 2 | 5 | Completed 3, Terminated 2 |
Follow BKM120: new trials by email Literature Review of BKM120 trials Research Report on BKM120
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors AN2025, AN0025, Atezolizumab 1200 mg in 20 ML Injection - Locally Advanced Solid Tumor | Phase 1 | Completed | Adlai Nortye Biopharma Co., Ltd. | 47 | 2021-09-07 | 2025-06-22 |
| Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Buparlisib, Ibrutinib, Ofatumumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 | Terminated | Emory University | 1 | 2016-01-01 | 2019-09-03 |
| Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors Buparlisib, Cisplatin, Gemcitabine Hydrochloride - Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2015-09-01 | 2023-04-27 | |
| Phase I BKM120/Abraxane in Solid Tumors, Expansion Phase Recurrent Endometrial or Ovarian Cancer BKM120, Nabpaclitaxel - Ovarian Cancer, Endometrial Cancer | Phase 1 | Withdrawn | Rutgers, The State University of New Jersey | 2015-02-01 | 2022-07-28 | |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT) - Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 23 | 2014-09-29 | 2026-11-05 |
| Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma PI3K inhibitor BKM120, rituximab, Pharmacodynamics - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 1 | Completed | Kami Maddocks, MD | 18 | 2014-07-21 | 2022-06-30 |
| Cisplatin, Etoposide and PI3K Inhibitor BKM120 in Treating Patients With Advanced Solid Tumors or Small Cell Lung Cancer BKM120, cisplatin, etoposide - Extensive Stage Small Cell Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | University of California, Davis | 3 | 2014-07-01 | 2018-01-09 |
| Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer LEE011, BYL719, fulvestrant - Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 70 | 2014-05-19 | 2020-12-17 |
| Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment. Buparlisib - Renal Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 19 | 2014-03-01 | 2020-12-09 |
| Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma INC280, Buparlisib - c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 43 | 2014-01-09 | 2018-05-30 |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Buparlisib, Buparlisib matching placebo, Docetaxel - Squamous Non-small Cell Lung Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 27 | 2013-10-01 | 2018-08-14 |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Buparlisib, Buparlisib placebo, Carboplatin - Non-Small Cell Lunch Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 6 | 2013-09-09 | 2018-10-11 |
| PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer PI3K inhibitor BKM120, pemetrexed disodium, carboplatin - Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 | Completed | City of Hope Medical Center | 9 | 2013-07-01 | 2016-09-20 |
| PI3K Inhibitor BKM120 and Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer PI3K inhibitor BKM120, cetuximab - Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary | Phase 1 / Phase 2 | Completed | University of Chicago | 12 | 2013-05-01 | 2021-10-05 |
| Palliative Thoracic Radiotherapy Plus BKM120 BKM120 - Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | University of Oxford | 21 | 2013-04-01 | 2019-08-01 |
| A Study to Find the Maximum Tolerated Dose of the Experimental Combination of the Drugs INC424 and BKM120 in Patients With Primary or Secondary Myelofibrosis INC424, BKM120 - Myelofibrosis | Phase 1 | Terminated | Novartis Pharmaceuticals | 63 | 2012-12-18 | 2020-12-19 |
| BKM120+Abiraterone Acetate for Metastatic CRPC BKM120, Abiraterone, Prednisone - Prostate Cancer | Phase 1 | Terminated | Dana-Farber Cancer Institute | 4 | 2012-11-01 | 2019-02-05 |
| P13Kinase Inhibitor BKM120 in Combination With Panitumumab in Metastatic/Advanced RAS-Wild Type Colorectal Cancer. BKM120, Panitumumab - Metastatic Colorectal Cancer | Phase 1 / Phase 2 | Completed | Canadian Cancer Trials Group | 22 | 2012-09-06 | 2023-08-04 |
| Phase Ib of Abiraterone Acetate Plus BEZ235 or BKM120 in Castration-resistant Prostate Cancer (CRPC) Patients BEZ235, BKM120 - Castration-resistant Prostate Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 43 | 2012-09-01 | 2020-12-09 |
| Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors LDE225, BKM120 - Dose Escalation, Safety | Phase 1 | Completed | Novartis Pharmaceuticals | 120 | 2012-07-01 | 2020-12-19 |
Showing 20 of 35. Sign in to see all of them.
Breast Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (4) · Colorectal Neoplasms (4) · Glioblastoma (3) · Neoplasm Metastasis (3) · Brain Neoplasms (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Colonic Neoplasms (1) · Esophageal Neoplasms (1) · Gliosarcoma (1) · Hereditary Sensory and Autonomic Neuropathies (1)
Novartis Pharmaceuticals (15) · Dana-Farber Cancer Institute (2) · Emory University (2) · Roswell Park Cancer Institute (2) · Adlai Nortye Biopharma Co., Ltd. (1) · Canadian Cancer Trials Group (1) · City of Hope Medical Center (1) · Kami Maddocks, MD (1) · M.D. Anderson Cancer Center (1) · Rutgers, The State University of New Jersey (1) · SCRI Development Innovations, LLC (1) · UNC Lineberger Comprehensive Cancer Center (1) · University of California, Davis (1) · University of Chicago (1) · University of Kansas Medical Center (1)
United States (27) · Spain (11) · Canada (7) · Germany (7) · United Kingdom (7) · Belgium (6) · France (6) · Italy (6) · Netherlands (3) · Australia (2) · Bulgaria (2) · Japan (2) · Singapore (2) · South Korea (2) · Switzerland (2)
Alex Adjei (2) · Autumn McRee, MD (1) · Cynthia Ma (1) · Darlene Gibbon, MD (1) · Derek Jonker (1) · Geoff Higgins, MRCP, FRCR, D.Phil (1) · Glenn Bubley, MD (1) · Ingrid Mayer, MD (1) · Joaquina Baranda, MD (1) · Jonathon Cohen, MD, MS (1) · Kami Maddocks, MD (1) · Karen Kelly (1) · Karen Reckamp (1) · Kent Shih, MD (1)
PMID 26098748, PMID 31506897, PMID 31776899, PMID 32147671, PMID 32887722, PMID 33004905
2009 (2), 2008 (1)